Can a dual protein blocker shrink Hard-to-Treat tumors?

NCT ID NCT05598151

Ongoing Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called HM97662 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking two proteins, EZH1 and EZH2, which are thought to help tumors grow. The study aims to find the safest dose, understand how the drug behaves in the body, and see if it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HM97662, an experimental drug that blocks two proteins (EZH1 and EZH2) involved in tumor growth
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase trial, so the drug may not work as hoped or may cause unexpected side effects. Results are preliminary and need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Locations

Asan Medical Center

Seoul, South Korea
Cancer Research SA

Adelaide, Australia
Grampians Health

Ballarat, Australia
Monash Medical Centre

Clayton, Australia
National Cancer Center

Goyang-si, Gyeonggi-do, South Korea
Peninsula and Southeast Oncology

Frankston, Australia
Samsung Medical Center

Seoul, South Korea
Seoul National University Bundang Hospital

Seoul, South Korea
Seoul National University Hospital

Seoul, South Korea
The Catholic University of Korea, Seoul ST. Mary's Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.